Prosecution Insights
Last updated: April 19, 2026
Application No. 17/747,397

METHODS OF EVALUATING BRAIN INJURY IN A PEDIATRIC SUBJECT

Final Rejection §101§112§DP
Filed
May 18, 2022
Examiner
CHERNYSHEV, OLGA N
Art Unit
1675
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Abbott Laboratories
OA Round
2 (Final)
54%
Grant Probability
Moderate
3-4
OA Rounds
3y 2m
To Grant
89%
With Interview

Examiner Intelligence

Grants 54% of resolved cases
54%
Career Allow Rate
512 granted / 942 resolved
-5.6% vs TC avg
Strong +34% interview lift
Without
With
+34.4%
Interview Lift
resolved cases with interview
Typical timeline
3y 2m
Avg Prosecution
44 currently pending
Career history
986
Total Applications
across all art units

Statute-Specific Performance

§101
14.8%
-25.2% vs TC avg
§103
8.6%
-31.4% vs TC avg
§102
12.6%
-27.4% vs TC avg
§112
45.6%
+5.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 942 resolved cases

Office Action

§101 §112 §DP
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Response to Amendment 1. Claims 1, 2, 12, 14, 15 and 22 have been amended and claim 11 canceled as requested in the amendment filed on November 07, 2025. Following the amendment, claims 1, 2, 7-9, 12-15, 20-24, 26, 28, 29, 31, 33 and 34 are pending in the instant application. 2. Claims 1, 2, 7-9, 12-15, 20-24, 26, 28, 29, 31, 33 and 34 are under examination in the instant office action. 3. Any objection or rejection of record, which is not expressly repeated in this action has been overcome by Applicant’s response and withdrawn. 4. Applicant’s arguments filed on November 07, 2025 have been fully considered but they are not deemed to be persuasive for the reasons set forth below. New grounds of rejection necessitated by Applicant’s amendment are set forth below as well. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. 5. 1, 2, 7-9, 12, 13, 20, 22-24, 26, 28, 29, 31, 33 and 34, as amended, are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. 6. Claim 1 has been amended to recite a method of performing an assay comprising performing an assay and identifying a subject as having certain levels of GFAP and UCH-L1 as greater than reference levels. In the current context, the claim does not allow clear interpretation of what stands for “identifying the subject as having” certain levels of factors in a sample, and further what stands for a “reference level.” Applicant is advised that if a claim is intended to measuring of the levels of factors in a sample obtained from a subject, then this is what the claim should recite to avoid ambiguity of interpretation of the claimed subject matter. 7. Claim 20 stands rejected for reasons of record in section 4 of Paper mailed on May 09, 2025. Applicant traverses the rejection on the premises that the claim has been either amended or canceled, p. 15 of the Response. However, claim 20 stans as “Previously presented,” and as such the rejection is maintained. 8. Claims 2, 7-9, 12, 13, 22-24, 26, 28, 29, 31, 33 and 34 are indefinite for being dependent from indefinite claim. Claim Rejections - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. 9. Claims 14-15 and 20-21 stand rejected under 35 U.S.C. 101 because the claimed invention is directed to a judicial exception (i.e., a law of nature, a natural phenomenon, or an abstract idea) without significantly more for reasons of record in section 6 of Paper mailed on May 0, 2025. Applicant traverses the rejection at p. 16 of the Response, by stating that claim 14 has been amended to recite “performing a head computerized tomography,” which remedies the rejection of record. While this has been fully considered, the argument is not persuasive for reasons that follow. As fully explained earlier, to satisfy prong two of Step 2A of the subject matter patentability analysis, the claims must satisfy the requirement of “integration in to a practical application.” In the instant case, the claims do not recite any additional elements to integrate the judicial exception into a practical application because all the steps of the claimed methods are limited to only those that measure naturally occurring factors during a naturally occurring pathology. (Step 2A/2: No). Note that performing an assay on a patient reads on judicial exception, such as observing the changes that occur naturally during pathology of head injury. For reasons fully explained earlier and reasons above, the rejection is maintained. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. 10. Claims 1, 2, 7-9, 11-15, 20-24, 26, 28, 29, 31, 33 and 34 stand rejected on the ground of nonstatutory double patenting as being unpatentable over claims of the following issued US Patents: U.S. Patent No. 10,849,548; 10,866,251;10,877,038; 10,877,048; 11,016,092; 11,016,105; 11,022,617; 11,931,161; 12,085,567; 12,092,647; 12,099,069; 12,105,098; 12,105,100 and 12,163,958 for reasons of record in section 8 of Paper mailed on May 09, 2025. Conclusion 11. No claim is allowed. 12. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to OLGA N CHERNYSHEV whose telephone number is (571)272-0870. The examiner can normally be reached 9AM to 5:30PM, Monday to Friday. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Stucker can be reached at (571)272-0911. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /OLGA N CHERNYSHEV/ Primary Examiner, Art Unit 1675 January 26, 2026
Read full office action

Prosecution Timeline

May 18, 2022
Application Filed
May 06, 2025
Non-Final Rejection — §101, §112, §DP
Nov 07, 2025
Response Filed
Jan 26, 2026
Final Rejection — §101, §112, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12601750
DIAGNOSING MILD COGNITIVE IMPAIRMENT (MCI), PREDICTING ALZHEIMER'S DISEASE (AD) DEMENTIA ONSET, AND SCREENING AND MONITORING AGENTS FOR TREATING MCI OR PREVENTING DEMENTIA ONSET
2y 5m to grant Granted Apr 14, 2026
Patent 12601751
PROTEIN ANTIGEN COMBINATION FOR DETECTION OF ALZHEIMER'S DISEASE AND APPLICATION THEREOF
2y 5m to grant Granted Apr 14, 2026
Patent 12596126
METHODS FOR THE PREDICTION, PROGNOSIS, AND/OR DIAGNOSIS OF AN INFLAMMATORY RESPONSE ASSOCIATED WITH SCHIZOPHRENIA
2y 5m to grant Granted Apr 07, 2026
Patent 12589098
METHODS OF TREATING PRADER WILLI SYNDROME AND CONDITIONS ASSOCIATED WITH LOW BASAL METABOLIC RATE OR HYPERPHAGIA USING A KATP CHANNEL OPENER
2y 5m to grant Granted Mar 31, 2026
Patent 12582693
GLUTATHIONE TRISULFIDE (GSSSG) IN NEUROPROTECTION
2y 5m to grant Granted Mar 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
54%
Grant Probability
89%
With Interview (+34.4%)
3y 2m
Median Time to Grant
Moderate
PTA Risk
Based on 942 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month